Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg)

Targeted Oncology

Volumn 10, Issue 2, 2015, Pages 277-286

  Donini, M ^a   Buti, S ^a,b   Lazzarelli, S ^a   Bozzetti, R ^a   Rivoltini, L ^c   Camisaschi, C ^c   Castelli, C ^c   Bearz, A ^d   Simonelli, C ^d,e   Lo Re, G ^f   Mattioli, R ^g   Caminiti, C ^h   Passalacqua, R ^a  

^a Oncology Division   (Italy)

^b Azienda Ospedaliero Universitaria di Parma   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^e Menarini Ricerche SpA   (Italy)

^f S MARIA DEGLI ANGELI HOSPITAL   (Italy)

^g Oncology Unit Azienda Ospedaliera Santa Croce   (Italy)

^h Research and Innovation Unit   (Italy)

Author keywords

Bevacizumab; Chemotherapy; Immunotherapy; Renal cell cancer; Treg

Indexed keywords

ALPHA2A INTERFERON; BEVACIZUMAB; FLUOROURACIL; GEMCITABINE; INTERLEUKIN 2; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; RECOMBINANT PROTEIN;

ADULT; AGED; ALLERGIC REACTION; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CARDIOTOXICITY; CONSTIPATION; COUGHING; DEEP VEIN THROMBOSIS; DEPRESSION; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EPISTAXIS; EVENING DOSAGE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEADACHE; HEMATURIA; HEMOPTYSIS; HUMAN; HUMAN CELL; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOALBUMINEMIA; HYPOTENSION; KIDNEY CANCER; KIDNEY FAILURE; LEUKOPENIA; LOW DRUG DOSE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METASTATIC RENAL CELL CANCER; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; RECOMMENDED DRUG DOSE; REGULATORY T LYMPHOCYTE; RISK ASSESSMENT; SKIN TOXICITY; THROMBOCYTOPENIA; THROMBOPHLEBITIS; TREATMENT OUTCOME; TREATMENT RESPONSE; VERY ELDERLY; VOMITING; ADJUVANT CHEMOTHERAPY; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; CARCINOMA, RENAL CELL; CELL SEPARATION; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG EFFECTS; FLOW CYTOMETRY; IMMUNOLOGY; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; ITALY; KAPLAN MEIER METHOD; KIDNEY NEOPLASMS; MIDDLE AGED; MORTALITY; NEPHRECTOMY; PATHOLOGY; PROCEDURES; TIME FACTOR;

ADMINISTRATION, INTRAVENOUS; ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CARCINOMA, RENAL CELL; CELL SEPARATION; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; FLUOROURACIL; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; INTERLEUKIN-2; ITALY; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEPHRECTOMY; RECOMBINANT PROTEINS; T-LYMPHOCYTES, REGULATORY; TIME FACTORS; TREATMENT OUTCOME;

EID: 84930673064     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-014-0337-6     Document Type: Article

References (37)

1. Lilleby W, Fossa SD (2005) Chemotherapy in metastatic renal cell cancer. World J Urol 23:175–179
2. Amato RJ (2005) Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens. Ann Oncol 16(7–1516):7–15
3. Buti S, Brighenti M, Bongiovanni C et al (2007) Role of chemotherapy with gemcitabine plus 5-fluorouracil and chemoimmunotherapy in metastatic renal cell cancer. J Immunother 30:780–786
4. Buzaid AC, Todd MB (1989) Therapeutic options in renal cell carcinoma. Semin Oncol 16(1):12–19
5. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58–62
6. Motl S (2005) Bevacizumab in combination chemotherapy for colorectal and other cancers. Am J Health Syst Pharm 62:1021–1032
7. Buti S, Lazzarelli S, Chiesa MD et al (2010) Dose-finding trial of a combined regimen with Bevacizumab, immunotherapy, and chemotherapy in patients with metastatic renal cell cancer: an Italian oncology group for clinical research (GOIRC) study. J Immunother 33(7):735–741
8. Aoyamaa A, Klarina D, Yamadaa Y et al. Low-dose IL-2 for in vivo expansion of CD4+ and CD8+ regulatory T cells in nonhuman primates. American Journal of Transplantation Brief Communication doi: 10.1111/j.1600-6143.2012.04133.x
9. Rowe JH, Ertelt JM, Way SS (2012) Foxp3+ regulatory T cells, immune stimulation and host defence against infection. Immunology 136(1):1–10
10. Xia Liu, Xun Xu, Xin Lin et al. PTD-hFOXP3 protein acts as an immune regulator to convert human CD4+CD25- T cells to regulatory T-like cells. Journal of cellular biochemistry. doi:10.1002/jcb.24255
11. Liu VC, Wong LY, Jang T et al (2007) Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. J immunol 1 178(5):2883–2892
12. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors: European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada. J Natl Cancer Inst 92:205–216
13. NCI Common Terminology Criteria for Adverse Events v3.0 (CTCAE) Publish Date: December 12, 2003. http://ctep.cancer.gov/reporting/ctc.html.
14. Motzer RJ, Mazumdar M, Bacik J et al (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17(8):2530–2540
15. Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124
16. Escudier B, Eisen T, Stadlre WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125–134
17. Escudier B, Pluzanska A, Koralewski P et al (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370:2103–2111
18. Rini BI, Halabi S, Rosenberg JE et al (2008) Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26:5422–5428
19. Sternberg CN, Davis ID, Mardiak J et al (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28:1061–1068
20. Rini B, Escudier B, Tomczak P et al (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomized phase 3 trial. Lancet 2011 378(9807):1931–1939. doi:10.1016/S0140-6736(11)61613-9
21. Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal cell carcinoma. N Engl J Med 356:2271–2281
22. Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-cont rolled phase III trial. Lancet 372:449–456
23. Motzer RJ, Hutson TE, Tomczak P et al (2009) Overall survival and updated results for sunitinib compared with interferon alpha in patients with metastatic renal cell carcinoma. J Clin Oncol 27(22):3584–3590
24. Dandamudi UB, Ghebremichael M, Sosman JA et al (2013) A phase II study of Bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a cytokine working group (CWG) study. J Immunother 36(9):490–495. doi:10.1097/CJI.0000000000000003
25. Cameron RB, McIntosh JK, Rosenberg SA (1988) Synergic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases. Cancer Res 48:5810–5817
26. Rini BI, Weinberg V, Small EJ (2005) A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma. Cancer 103:553–558
27. Tannir NM, Thall PF, Ng CS et al (2008) A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. J Urol 180:867–872
28. Soga N, Yamada Y, Nishikawa K et al (2009) Gemcitabine and capecitabine chemotherapy in Japanese patients with immunotherapy-resistant renal cell carcinoma. Int J Urol 16:576–579
29. Buti S, Bersanelli M, Sikokis A et al (2013) Chemotherapy in metastatic renal cell carcinoma today? A systemic review. Anti-Cancer Drugs 24(6):535–554. doi:10.1097/CAD.0b013e3283609ec1
30. Stadler WM (1995) Low-dose interleukin-2 in the treatment of metastatic renal-cell carcinoma. Semin Oncol 22:67–73
31. Vogelzang NJ, Lipton A, Figlin RA (1993) Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial. J Clin Oncol 11:1809–1816
32. Tempero M, Plunkett W, Ruiz Van Haperen VW et al (2003) Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21:3402–3408
33. Ahmadzadeh M, Rosenberg SA (2006) IL-2 administration increases CD4+CD25highFOXP3+ regulatory T cells in cancer patients. Blood 107:2409–2414
34. Guangxian Liu, Wuwei Yang, Mei Guo et al. Effective modulation of CD4+CD25+high regulatory T and NK cells in malignant patients by combination of interferon-a and interleukin-2. Cancer Immunol Immunother doi 10.1007/s00262-012-1297-2
35. Sanarico N, Ciamarella A, Sacchi A et al (2006) Human monocyte-derived dendritic-cells differentiated in the presence of IL-2 produce proinflammatory cytokines and prime Th1 immune response. J Leukoc Biol 80:555–562
36. Yamazaki S, Steinman RM (2009) Dendritic cells as controllers of antigen-specific Foxp3+ regulatory T cells. J Dermatol Sci 54:69–75
37. Sabbatino M, Kim-Schulze S, Panelli MC et al (2009) Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. JCO 27:2645–2652